Peak Wellness review

Identify the decision the service adds to care

Peak Wellness offers semaglutide and tirzepatide compounds through its weight-care site and a separate NAD+ program. These are distinct prescriptions. The number of available products does not establish that several belong in the same preventive plan. ^{[1] [2]}

Start with the actual purpose: an appropriate weight-care intervention, an unresolved symptom needing assessment, or a question about a proposed additional treatment. A broad goal such as healthier aging cannot by itself select a prescription or determine useful monitoring.

Compare the defined role in our health-service comparisons.

Separate the platform from the clinical team

The terms describe Peak as a referral and administrative platform rather than the medical provider or pharmacy. The process names DrTelX and identifies Emerald as its main dispenser, while allowing a wider pharmacy network. Confirm the practice, clinician and pharmacy assigned to the actual order. ^{[3] [4]}

The service describes check-ins and a business-hours support target, but its telehealth consent recognizes limitations and possible need for other care. Do not treat delivery updates or a fast review target as a substitute for comprehensive clinical follow-up. Coordinate the plan with existing healthcare. ^{[3] [7]}

For a different metabolic-care and add-on model, read our OrderlyMeds review.

Compare the complete term for each product

The monthly weight-care options list semaglutide at $179 initially then $249, and tirzepatide at $279 then $349. The selected tirzepatide view shows $837 for three months and $1,397 for six. The displayed equivalents are not separate installments. ^[1]

The NAD+ program has its own $199 one-month tier and lower $179/$149 monthly equivalents for three/six months. Establish each actual debit, supply and selected renewal schedule. A collection of starting figures is not a complete price for preventive care or a combined clinical package. ^[2]

Separate the actual commitments in the full care-cost planner.

Keep clinical outcomes separate from mechanisms

The weight-care homepage displays percentages and a transformation calculator beside compounded prescriptions. Its NAD+ page describes energy biology and a subcutaneous route while acknowledging early human clinical evidence. Neither display establishes longer healthy life or improved function from the selected compound. ^{[1] [2]}

FDA does not review compounded medicines before marketing for safety, effectiveness and quality. It recommends compounded GLP-1 medicines only when an approved drug cannot meet a patient’s medical needs. Pharmacy badges, a familiar molecule or branded-drug results cannot answer the finished-product outcome question. ^{[8] [9]}

Keep product and population attached to the SELECT cardiovascular evidence.

Distinguish measured outcomes with lean mass and physical function.

Understand the commitment before a long term

The process page describes a card preauthorization with collection after approval and release of a denied application’s hold. The subscription terms then allow automatic renewal, early processing and cancellation only with advance notice before the applicable processing date. ^{[3] [4]}

Ordinary partial-period refunds are excluded, and prescription sales are final under the returns policy. Cancellation, pausing and replacing a damaged order are therefore different from a refundable trial or a guarantee of results. Have the selected agreement settle the actual charge and exit dates. ^{[4] [5]}

Consider continuity alongside the evidence after GLP-1 treatment stops.

Judge the useful clinical addition

I would compare Peak after defining the intervention and how its review process helps a real decision. A patient-reported symptom, a biomarker change and a clinical event are different outcomes. Their meaning cannot be pooled into a general longevity promise.

The practical strengths to investigate are the stated care pathway, an identifiable supply relationship and the selected complete bill. The evidence still needs to match the specific product and person. A longer prepaid offer is attractive only if that care remains useful and financially workable.

For another catalogue and care relationship, compare our Raeliva review.

For a broader prescription catalogue and care arrangement, read our Polly review.

Understanding the cost

Monthly GLP-1 options advertise semaglutide $179 initially/$249 ongoing and tirzepatide $279/$349. Tirzepatide three/six-month totals are $837/$1,397; other equivalents require selected-total confirmation. Separate NAD+ tiers advertise $199 for one month and $179/$149 monthly equivalents for three/six months. Do not combine these into an unconfirmed complete preventive-care price. ^{[1] [2] [4]}